Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control After Acute Stroke

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-12-31

Study Completion Date

2018-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hyperglycemia is common during acute ischemic stroke. However, the optimal strategy to control hyperglycemia during acute ischemic stroke has not been established. The object of this multicenter randomized controlled study is to determine the efficacy and safety of early initiation of subcutaneous once-daily insulin glargine, in comparison with regular insulin, based on a protocolized sliding scale regimen to achieve proper sugar control in acute stroke patients with hyperglycemia admitted to the intensive care unit.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Insulin for Hyperglycemia in Stroke Trial

NCT04834362

Hyperglycemia Stroke, Acute

COMPLETED PHASE4

Intensive Insulin Therapy With Tight Glycemic Control to Improve Outcomes After Endovascular Therapy for Acute Ischemic Stroke

NCT02054429

Ischemic Stroke

COMPLETED PHASE1

Hyperglycemia as a Prognostic Factor In Acute Ischemic Stroke Patients

NCT04196322

Acute Ischemic Stroke Patients

COMPLETED

Identifying the Brain Substrates of Hypoglycemia Unawareness in Type 1 Diabetes

NCT02866435

Hypoglycemia

COMPLETED EARLY_PHASE1

Efficacy and Safety of Continuous Intravenous Versus Usual Subcutaneous Insulin in Acute Ischemic Stroke

NCT00472381

Acute Stroke Acute Cerebral Ischemia

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Rationale: Hyperglycemia is common during acute ischemic stroke. It has been shown that persistent in-hospital hyperglycemia during the first 24 hours (h) after stroke is associated with worse outcomes than normoglycemia. However, the optimal strategy to control hyperglycemia during acute ischemic stroke has not been established.

Aims: The object of this multicenter randomized controlled study is to determine the efficacy and safety of early initiation of subcutaneous once-daily insulin glargine, in comparison with regular insulin, based on a protocolized sliding scale regimen to achieve proper sugar control in acute stroke patients with hyperglycemia admitted to the intensive care unit (ICU).

Design: This is a 3-year, randomized, multicenter trial. Approximate 120 hyperglycemic acute stroke patients will receive either (a) subcutaneous long acting basal insulin (insulin glargine) with added short acting regular insulin to correct hyperglycemic events or (b) short acting regular insulin pre-meal with added NPH at bed time if start eating, for 72 h, starting within 24 h of stroke symptom onset. The inclusion criteria are patients who admitted to stroke ICU within 24 hours of acute stroke onset and have repeated random blood glucose \>200 mg/dL with a 2 hours interval. The exclusion criteria include patients with age \<20 years, pregnancy, shock, severe infection, end stage renal disease requiring dialysis, type I DM or current steroid usage. Capillary blood glucose will be measured every 4-hours to adjust the next insulin dose. Glucometric parameters will also be analyzed by continuous blood glucose monitoring system. 10 ml blood and same amount of urine from 24 hours urine collection will be collected every day for further measurement of a variety of blood inflammatory markers and urine catecholamine levels.

Study outcomes: The primary endpoint is the percentage of time in the range of 80-180 mg/dL during the sugar monitoring period. The secondary endpoints include: (1) good functional outcome at 3 months post stroke (modified Rankin Scale \<2), (2) stroke in evolution, (3) 24 hours blood glucose variability via continuous glucose monitoring, and (4) blood and urine biomarkers.

In summary, this trial will provide important novel information about preferred management of acute ischemic stroke patients with hyperglycemia. It will determine the potential benefits and risks of application of long acting basal insulin during very early stage of acute stroke.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Stroke Hyperglycemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Insulin Glargine

subcutaneous long acting basal insulin (insulin glargine) with added short acting regular insulin to correct hyperglycemic events

Group Type EXPERIMENTAL

Insulin Glargine

Intervention Type DRUG

Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control

Regular Insulin

short acting regular insulin pre-meal with added NPH at bed time if start eating

Group Type ACTIVE_COMPARATOR

Regular Insulin

Intervention Type DRUG

Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Insulin Glargine

Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control

Intervention Type DRUG

Regular Insulin

Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lantus

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who admitted to stroke ICU within 24 hours of acute stroke onset and have repeated random blood glucose \>200 mg/dL with a 2 hours interval

Exclusion Criteria

* Patients with age \<20 years,
* pregnancy,
* shock, severe infection, end stage renal disease requiring dialysis,
* type I DM or current steroid usage.

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No